Cisplatin plus paclitaxel and bevacizumab versus carboplatin plus paclitaxel and bevacizumab for the first-line treatment of metastatic or recurrent cervical cancer
Erişim
info:eu-repo/semantics/closedAccessTarih
2022Yazar
İlhan, YusufTatlı, Ali Murat
Teker, Fatih
Önder, Arif Hakan
Köse, Fatih
Geredeli, Çağlayan
Karaağaç, Mustafa
Kaplan, Muhammet Ali
İnanç, Mevlüde
Göktaş Aydın, Sabin
Kargı, Ayşegül
Arak, Hacı
Özturk, Banu
Beşen, Ali Ayberk
Selvi, Oğuzhan
Korkmaz, Mustafa
Oruç, Zeynep
Bozkurt, Oktay
Bilici, Ahmet
Bayram, Selami
Dae, Shute Ailia
Özdoğan, Mustafa
Coşkun, Hasan Şenol
Sezgin Göksu, Sema
Üst veri
Tüm öğe kaydını gösterKünye
İlhan, Y., Tatlı, A. M., Teker, F., Önder, A. H., Köse, F. ve Geredeli, Ç. (2022). Cisplatin plus paclitaxel and bevacizumab versus carboplatin plus paclitaxel and bevacizumab for the first-line treatment of metastatic or recurrent cervical cancer. International Journal of Gynecological Cancer, 32(4), 502-507. https://doi.org/10.1136/ijgc-2021-003165Özet
OBJECTIVE: Cisplatin-paclitaxel and bevacizumab is a frequently used treatment regimen for metastatic or recurrent cervical cancer, and carboplatin-paclitaxel and bevacizumab are also among the recommended regimens. In this study we aimed to evaluate the efficacy of these two regimens for the treatment of metastatic or recurrent cervical cancer. METHODS: Patients with metastatic or recurrent cervical cancer treated with cisplatin-paclitaxel and bevacizumab or carboplatin-paclitaxel and bevacizumab were retrospectively evaluated in this study. The clinical and demographic characteristics of patients in each group were evaluated. Median overall survival, progression-free survival, and response rates between the two groups were compared. RESULTS: A total of 250 patients were included. Overall, the numbers of patients with recurrent disease and metastatic disease were 159 and 91, respectively. The most common histologic subtype was squamous cell carcinoma (83.2%). The median duration of follow-up was 13.6 (range 0.5-86) months. The median progression-free survival was 10.5 (95% CI 9.0 to 11.8) months in the cisplatin-paclitaxel and bevacizumab group (group 1), and 10.8 (95% CI 8.6 to 13.0) months in the carboplatin-paclitaxel and bevacizumab group (group 2) (HR 1.20; 95% CI 0.88 to 1.63; p=0.25). The median overall survival was 19.1 (95% CI 13.0 to 25.1) months in group 1 and 18.3 (95% CI 15.3 to 21.3) months in group 2 (HR 1.28; 95% CI 0.91 to 1.80; p=0.15). CONCLUSIONS: There is no survival difference between cisplatin or carboplatin combined with paclitaxel and bevacizumab in metastatic or recurrent cervical cancer.
WoS Q Kategorisi
Q2Scopus Q Kategorisi
Q1Kaynak
International Journal of Gynecological CancerCilt
32Sayı
4Koleksiyonlar
- Makale Koleksiyonu [3651]
- PubMed İndeksli Yayınlar Koleksiyonu [4049]
- Scopus İndeksli Yayınlar Koleksiyonu [6285]
- WoS İndeksli Yayınlar Koleksiyonu [6432]